{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-019773","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.337889+00:00","generated_at":"2026-05-15T01:11:01.082825+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FDA clears IND for Telomir-Zn in advanced triple-negative breast cancer; Phase 1/2 trial planned for 1H 2026","bullets":["FDA cleared IND for lead candidate Telomir-Zn in advanced/metastatic triple-negative breast cancer.","Phase 1/2 trial to enroll ~76 patients; Phase 1 dose-escalation, Phase 2 primary endpoint ORR.","Planned initiation in first half of 2026 at a leading US academic medical center.","Preclinical data included pharmacology, toxicology, PK, and biomarker analyses.","Translational biomarker program to assess epigenetic modulation and telomere dynamics."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-019773","json":"https://secwatch.observer/filing/0001493152-26-019773.json","markdown":"https://secwatch.observer/filing/0001493152-26-019773.md","text":"https://secwatch.observer/filing/0001493152-26-019773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226019773/0001493152-26-019773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226019773/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:11:01.082825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}